Blog

How to choose retatrutide、semaglutide、tirzepatide？

Writer： admin Time：2025-06-20 15:24 Browse：℃

Retatrutide: It is a triple receptor agonist for glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1)/glucagon (GCG). By acting on these three receptors simultaneously, it can more comprehensively regulate human metabolism. Theoretically, it can reduce appetite, increase energy expenditure, and improve the body's handling of glucose, especially with a more potent effect on GIP receptors.
Semaglutide: As a GLP-1 receptor agonist, it mainly exerts its effect by selectively binding to and activating GLP-1 receptors. It promotes insulin synthesis and secretion in a glucose-dependent manner, inhibits glucagon secretion, suppresses appetite and food intake, and delays gastric emptying, thereby reducing the rate of postprandial blood glucose rise.
Tirzepatide: It is a dual receptor agonist for GLP-1 and GIP, combining the mechanisms of action of both. On the one hand, it acts through GLP-1 receptors to suppress appetite, slow digestion, and enhance insulin secretion; on the other hand, it improves insulin sensitivity and glucose metabolism through GIP receptors.

Retatrutide: The proposed indication is to be used as an adjunct to diet and exercise for long-term weight management in adults with obesity or overweight combined with at least one weight-related comorbidity. It is still in the clinical trial stage and has not been approved for marketing.
Semaglutide: It has different indications and formulations. For example, Ozempic is used to adjunctively improve blood glucose levels in adults with type 2 diabetes, while Wegovy is used for long-term weight management in adults with an initial body mass index (BMI) ≥ 30 kg/m², or those with an initial BMI between 27 kg/m² and 30 kg/m² and at least one weight-related comorbidity (such as hypertension, type 2 diabetes, hypercholesterolemia, etc.).
Tirzepatide: It has been approved for the treatment of type 2 diabetes and also shows good performance in weight management. It is suitable for type 2 diabetes patients who need to control blood glucose and weight, as well as people with pure weight management needs.

Retatrutide: It has shown significant weight loss effects in clinical trials. In a phase 2 double-blind, randomized, placebo-controlled trial, participants receiving a 12 mg dose had an average weight loss of 24.2% at 48 weeks.
Semaglutide: When used for weight management, it can lead to an average weight loss of about 10%-15% within 68 weeks.
Tirzepatide: In a 72-week trial, different dose groups showed obvious dose-dependent weight loss. The 5 mg dose group had an average weight loss of 16.1 kg, the 10 mg dose group lost 22.2 kg, and the 15 mg dose group lost 23.6 kg. The overall weight loss effect is better than that of Semaglutide.

Retatrutide: Early trials have shown that it has the potential to reduce glycated hemoglobin (HbA1c) by more than 2.5%, enabling faster and more comprehensive blood glucose control.
Semaglutide: It can improve HbA1c levels by 1.5%-2%, and helps control postprandial blood glucose peaks through mechanisms such as delaying gastric emptying.
Tirzepatide: It can reduce HbA1c by 2.0%-2.3%, and is more effective than Semaglutide in blood glucose control. It provides broader metabolic benefits by enhancing insulin secretion and sensitivity.

Retatrutide: The most common adverse reactions are gastrointestinal reactions, such as nausea, diarrhea, vomiting, and constipation, mostly mild to moderate. Due to its activation of glucagon receptors, it may increase the risk of mild hypoglycemia, especially when used in combination with other hypoglycemic drugs.
Semaglutide: Common side effects are also gastrointestinal-related, including nausea, vomiting, diarrhea, constipation, etc., and may also cause discomfort such as headache and dizziness. Serious but rare side effects include pancreatitis, gallbladder problems, etc.
Tirzepatide: The side effects are similar to those of Semaglutide, mainly gastrointestinal reactions such as nausea, vomiting, diarrhea, constipation, etc. At high doses, it may cause more people to withdraw from the study due to side effects.